These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34587481)

  • 81. Erythrocytes identify complement activation in patients with COVID-19.
    Lam LKM; Reilly JP; Rux AH; Murphy SJ; Kuri-Cervantes L; Weisman AR; Ittner CAG; Pampena MB; Betts MR; Wherry EJ; Song WC; Lambris JD; Meyer NJ; Cines DB; Mangalmurti NS
    Am J Physiol Lung Cell Mol Physiol; 2021 Aug; 321(2):L485-L489. PubMed ID: 34231390
    [TBL] [Abstract][Full Text] [Related]  

  • 82. SARS-CoV2 pneumonia recovery is linked to expansion of innate lymphoid cells type 2 expressing CCR10.
    Gomes AMC; Farias GB; Dias-Silva M; Laia J; Trombetta AC; Godinho-Santos A; Rosmaninho P; Santos DF; Conceição CM; Costa-Reis R; Adão-Serrano M; Mota C; Almeida ARM; Sousa AE; Fernandes SM
    Eur J Immunol; 2021 Dec; 51(12):3194-3201. PubMed ID: 34564853
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The COVID-19 immune landscape is dynamically and reversibly correlated with disease severity.
    Bolouri H; Speake C; Skibinski D; Long SA; Hocking AM; Campbell DJ; Hamerman JA; Malhotra U; Buckner JH;
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33529167
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The case of complement inhibitors.
    Noris M
    Adv Biol Regul; 2021 Aug; 81():100822. PubMed ID: 34454870
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Tissue Proteomic Analysis Identifies Mechanisms and Stages of Immunopathology in Fatal COVID-19.
    Russell CD; Valanciute A; Gachanja NN; Stephen J; Penrice-Randal R; Armstrong SD; Clohisey S; Wang B; Al Qsous W; Wallace WA; Oniscu GC; Stevens J; Harrison DJ; Dhaliwal K; Hiscox JA; Baillie JK; Akram AR; Dorward DA; Lucas CD
    Am J Respir Cell Mol Biol; 2022 Feb; 66(2):196-205. PubMed ID: 34710339
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Hyper-inflammation and complement in COVID-19.
    Pires BG; Calado RT
    Am J Hematol; 2023 May; 98 Suppl 4():S74-S81. PubMed ID: 36999459
    [TBL] [Abstract][Full Text] [Related]  

  • 87. SARS-CoV-2 associated Complement genetic variants possibly deregulate the activation of the Alternative pathway affecting the severity of infection.
    Tsiftsoglou SA
    Mol Immunol; 2021 Jul; 135():421-425. PubMed ID: 33838929
    [No Abstract]   [Full Text] [Related]  

  • 88. Maturation signatures of conventional dendritic cell subtypes in COVID-19 suggest direct viral sensing.
    Marongiu L; Protti G; Facchini FA; Valache M; Mingozzi F; Ranzani V; Putignano AR; Salviati L; Bevilacqua V; Curti S; Crosti M; Sarnicola ML; D'Angiò M; Bettini LR; Biondi A; Nespoli L; Tamini N; Clementi N; Mancini N; Abrignani S; Spreafico R; Granucci F
    Eur J Immunol; 2022 Jan; 52(1):109-122. PubMed ID: 34333764
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Understanding the role of telomere attrition and epigenetic signatures in COVID-19 severity.
    Mahmoodpoor A; Sanaie S; Roudbari F; Sabzevari T; Sohrabifar N; Kazeminasab S
    Gene; 2022 Feb; 811():146069. PubMed ID: 34848322
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Targeting the Complement-Sphingolipid System in COVID-19 and Gaucher Diseases: Evidence for a New Treatment Strategy.
    Trivedi VS; Magnusen AF; Rani R; Marsili L; Slavotinek AM; Prows DR; Hopkin RJ; McKay MA; Pandey MK
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430817
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Dynamic control of the complement system by modulated expression of regulatory proteins.
    Thurman JM; Renner B
    Lab Invest; 2011 Jan; 91(1):4-11. PubMed ID: 20921948
    [TBL] [Abstract][Full Text] [Related]  

  • 92. The state of complement in COVID-19.
    Afzali B; Noris M; Lambrecht BN; Kemper C
    Nat Rev Immunol; 2022 Feb; 22(2):77-84. PubMed ID: 34912108
    [TBL] [Abstract][Full Text] [Related]  

  • 93. IP-10 and complement activation as friend or foe in COVID-19.
    Bunprakob S; Hemachudha P; Ruchisrisarod C; Supharatpariyakorn T; Hemachudha T
    Int J Immunopathol Pharmacol; 2022; 36():3946320221096202. PubMed ID: 35531750
    [TBL] [Abstract][Full Text] [Related]  

  • 94. From COVID-19 to clot: the involvement of the complement system.
    Hendaus MA; Jomha FA
    J Biomol Struct Dyn; 2022 Mar; 40(4):1909-1914. PubMed ID: 33063628
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Elevated IFNA1 and suppressed IL12p40 associated with persistent hyperinflammation in COVID-19 pneumonia.
    Jeon K; Kim Y; Kang SK; Park U; Kim J; Park N; Koh J; Shim MS; Kim M; Rhee YJ; Jeong H; Lee S; Park D; Lim J; Kim H; Ha NY; Jo HY; Kim SC; Lee JH; Shon J; Kim H; Jeon YK; Choi YS; Kim HY; Lee WW; Choi M; Park HY; Park WY; Kim YS; Cho NH
    Front Immunol; 2023; 14():1101808. PubMed ID: 36776879
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Hypotheses to explain the associations between asthma and the consequences of COVID-19 infection.
    Warner JO; Warner JA; Munblit D
    Clin Exp Allergy; 2022 Jan; 52(1):7-9. PubMed ID: 34978737
    [No Abstract]   [Full Text] [Related]  

  • 97. Diverse functional autoantibodies in patients with COVID-19.
    Wang EY; Mao T; Klein J; Dai Y; Huck JD; Jaycox JR; Liu F; Zhou T; Israelow B; Wong P; Coppi A; Lucas C; Silva J; Oh JE; Song E; Perotti ES; Zheng NS; Fischer S; Campbell M; Fournier JB; Wyllie AL; Vogels CBF; Ott IM; Kalinich CC; Petrone ME; Watkins AE; ; Dela Cruz C; Farhadian SF; Schulz WL; Ma S; Grubaugh ND; Ko AI; Iwasaki A; Ring AM
    Nature; 2021 Jul; 595(7866):283-288. PubMed ID: 34010947
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The role of the thymus in COVID-19 disease severity: implications for antibody treatment and immunization.
    Kellogg C; Equils O
    Hum Vaccin Immunother; 2021 Mar; 17(3):638-643. PubMed ID: 33064620
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Identification of COVID-19 subtypes based on immunogenomic profiling.
    Chen Z; Feng Q; Zhang T; Wang X
    Int Immunopharmacol; 2021 Jul; 96():107615. PubMed ID: 33836368
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Atopic status protects from severe complications of COVID-19.
    Scala E; Abeni D; Tedeschi A; Manzotti G; Yang B; Borrelli P; Marra A; Giani M; Sgadari A; Saltalamacchia F; Asero R
    Allergy; 2021 Mar; 76(3):899-902. PubMed ID: 32799364
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.